Related references
Note: Only part of the references are listed.NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry
D. Craig Allred et al.
Journal of the National Comprehensive Cancer Network (2017)
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Takayuki Iwamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study
James A. Kraus et al.
MODERN PATHOLOGY (2012)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Management of breast cancer with targeted agents: importance of heterogenicity
Serena Di Cosimo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer:: Predictive value of centrally reviewed expression of estrogen and progesterone receptors -: International Breast Cancer Study Group
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Re-evaluating adjuvant breast cancer trials:: Assessing hormone receptor status by immunohistochemical versus extraction assays
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Concordance among gene-expression-based predictors for breast cancer
Cheng Fan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
A. Buzdar et al.
LANCET ONCOLOGY (2006)
Breast pathology practice: most common problems in a consultation service
TC Putti et al.
HISTOPATHOLOGY (2005)
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
A Goldhirsch et al.
ANNALS OF ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
